Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation

20 Dec 2020

Abstract excerpt

Platinum-based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to chemotherapeutic drugs, we explored the mechanisms of acquired drug resistance to the Chk1 inhibitor prexasertib in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33320980
DOI: 10.1002/1878-0261.12882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulationPMID 33320980Read ↗

Synergistic cytotoxicity with Chk1/Chk2-inhibitor prexasertib in small cell lung cancer following lurbinectedin-induced G2/M-checkpoint activationSemantic proximity Read ↗

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerSemantic proximity Read ↗

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Treatment with the Chk1 inhibitor Gï¿½6976 enhances cisplatin cytotoxicity in SCLC cellsSemantic proximity Read ↗

Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screeningSemantic proximity Read ↗

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancerSemantic proximity Read ↗

Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedureSemantic proximity Read ↗

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Semantic proximity Read ↗

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.Semantic proximity Read ↗

Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung CancerSemantic proximity Read ↗

KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cellsSemantic proximity Read ↗

Drug resistance in lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.